Trial · NCT03197194
A Phase III Randomized, Blind, Double Dummy, Multicenter Study Assessing the Efficacy and Safety of IV THrombolysis (Alteplase) in Patients With acutE Central retInal Artery Occlusion
NCT03197194, Phase 3, Completed, Nantes University Hospital
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. A Phase III Randomized, Blind, Double Dummy, Multicenter Study Assessing the Efficacy and Safety of IV THrombolysis (Alteplase) in Patients With acutE Central retInal Artery Occlusion. Trials, record NCT03197194. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03197194
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Phase III Randomized, Blind, Double Dummy, Multicenter Study Assessing the Efficacy and Safety of IV THrombolysis (Alteplase) in Patients With acutE Central retInal Artery Occlusion
- NCT number
- NCT03197194
- Status
- Completed
- Phases
- Phase 3
- Enrollment
- 70 participants, actual
- Lead sponsor
- Nantes University Hospital
- Conditions
- Central Retinal Artery Occlusion
- Interventions
- Alteplase, acetylsalicylic acid, Placebo Oral Tablet, placebo IV
- First posted
- 2017-06-23
- Last updated
- 2024-01-24
Source ClinicalTrials.gov
Registered outcomes8
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | visual acuity (VA) improvement after treatment | 1 month | Improvement of the VA is defined by a gain of 15 letters or more on the ETDRS VA chart or ordinal scale |
| Secondary | Tolerance | 3 months | Number, type and grade of severity of adverse drug reactions |
| Secondary | Proportion of blindness patients after treatment | 1 month | Blindness is defined according to WHO revised categories of visual impairment, as VA \< 1/20 (\< 20/400 or \> 1.3 log.MAR) or visual field \< 10. |
| Secondary | Visual field | 3 months | Visual field at 3 months. |
| Secondary | Time course of VA on ETDRS chart or ordinal scale | 3 months | |
| Secondary | Time-to-treatment administration impact on VA evolution. | 1 month | Mean VA improvement according to the time between onset of sign and treatment administration |
| Secondary | Global disability (modified Rankin scale) after treatment | 3 months | |
| Secondary | Quality of life related to vision (NEI-VFQ-25) after treatment | 3 months |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers2
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT03197194
GET https://conductscience.org/api/trials/v1/NCT03197194/registered